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Abstract 
Background 
Childhood brain tumours have some of the longest time to diagnosis. A timely 
diagnosis may have a role in reducing anxiety in waiting for a diagnosis and 
subsequent morbidity and mortality. We investigated where the opportunities for an 
earlier diagnosis were, and for which anatomical locations this strategy will most 
likely to be effective. 
Methods 
A record-linkage cohort study of patients diagnosed aged 0–24 years with a primary 
intracranial tumour between 1989 and 2006 in England, using records from the 
National Cancer Registry linked to hospital admission records from Hospital Episode 
Statistics (HES, 1997–2006) and primary care consultation records from Clinical 
Practice Research Datalink (CPRD, 1989–2006). Relevant neurological 
presentations were extracted from HES and CPRD. Temporal changes in 
presentation rates were estimated in generalised additive models. 
Results 
Frequency of presentation began to increase six months before diagnosis in primary 
care and three months before diagnosis in hospital. Supratentorial and midline 
tumours had the longest presentation history before diagnosis. Peri-ventricular 
tumours presented frequently in hospital (rate ratio = 1.29 vs supratentorial tumours; 
95% CI = 1.12–1.48) or as an emergency (1.24; 1.01–1.51), and in primary care 
(1.12; 0.62–1.85). 
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Conclusions 
Opportunities for an earlier diagnosis are greater in supratentorial, midline or cranial 
nerve tumours, which have a longer presentation history than peri-ventricular, 
cerebellar or brainstem tumours. Common features before diagnosis include 
headache, convulsions, and growth or endocrine disorders. Focal neurological 
deficits are uncommon and emerge late in the pre-diagnosis period. 
MeSH keywords: brain neoplasms, signs and symptoms, early diagnosis, symptom 
assessment, oncology, epidemiology. 
Highlights 
 Peri-ventricular tumours have the highest presentation intensity. 
 Cerebellar or brainstem tumours are often of late sudden onset. 
 Non-localising features (convulsion, headaches, vomiting) predominate. 
 Focal neurological deficits are rarely seen.  
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1. Introduction 
Primary intracranial tumours account for 25% of all childhood cancers, and are 
associated with the greatest number of cancer deaths.1 This has generated 
substantial interests in improving the prognosis of intracranial tumours through earlier 
detection,2-8 and culminated in the identification of early diagnosis as one of the top 
10 priorities for clinical research in neuro-oncology by The James Lind Alliance and 
by the National Cancer Research Institute Brain Supportive and Palliative Care sub-
group in the United Kingdom.9 The James Lind Alliance is a non-profit making 
initiative bringing together patients, carers and clinicians to identify unanswered 
questions that they agree are most important.10 
Evidence on early diagnosis of intracranial tumours in children and young adults, and 
particularly its relationship with survival, is scarce because of the logistical cost in 
recruiting sufficient patients to create a traditional cohort for identifying earlier 
diagnostic opportunities. Advances in statistical methodology and computing power 
in linking routinely collected patient care records have enabled creation of a 
population-based cohort with histologically verified intracranial tumours for examining 
temporal changes in the symptoms and signs at each primary care or hospital visit, 
thus allowing us to investigate if an earlier diagnosis of an intracranial tumour would 
have been possible.11-14 Our aims are to investigate if such opportunities were limited 
to tumours in certain locations or existed uniformly for tumours in any location to 
tailor recommendations on early diagnosis for specific intracranial neoplasms. This 
will provide evidence for a more focused approach in developing guidelines and 
evaluating interventions on early diagnosis to achieve the maximum possible effect in 
the population. 
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2. Patients and Methods 
We identified patients aged 0–24 years when diagnosed in England with a benign, 
borderline or malignant primary intracranial tumour from the National Cancer 
Registry. We have included patients up to the age of 24 years as those patients are 
often managed in specialist teenage cancer units in the United Kingdom. 
Intracranial tumours were defined as those with a relevant morphology (diagnostic 
groups III, IX.b.2, IX.d.8 and X.a in the third edition of the International Classification 
of Childhood Cancer15) and arising from one of the following sites (the 9th or 10th 
revision of the International Classification of Diseases, ICD16, 17): the supratentorial 
compartment, midline, cerebellum, brainstem, ventricular system, meninges, cranial 
nerves and other intracranial sites. Records were excluded if they contained invalid 
dates or unknown sex or vital status. Records which failed Office for National 
Statistics validity checks, those of secondary or metastatic tumours, synchronous or 
multiple primary tumours were also excluded.18 
We obtained records of primary care consultations between 1989 and 2006 from 
Clinical Practice Research Datalink (CPRD), a database of longitudinal records of 
primary care consultations from over 600 practices from anywhere in the UK.19, 20 
Patient data in CPRD are representative of the UK population in age, sex and 
ethnicity (compared with UK Census 2011), with high level of validity in data on 
diagnoses (over 95% of cases confirmed in internal and external validations for 
neoplasms).20, 21 We also obtained records of admissions between 1997 and 2006 
from Hospital Episode Statistics (HES), which collates data on in-patient stays in 
National Health Service (NHS) hospitals in England.22 CPRD and HES records were 
linked to the National Cancer Registry by matching on NHS number, sex, date of 
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birth and postcode.23, 24 
2.1. Presentation rates 
Over 800 clinical features relevant to an intracranial tumour presentation were 
identified from manually searching the list of Read and ICD-10 codes.25 Read coding 
is a hierarchical system for coding symptoms, signs, diagnoses, interventions and 
administrative events in primary care. We retained for analysis records of primary 
care or hospital visits containing one or more coded features that may be explained 
by the presence of an underlying intracranial tumour. Each episode of hospital stay 
was also classified as “non-emergency” or “emergency” based on how the patient 
was admitted. An emergency admission came from any of the following sources: the 
Accident and Emergency department, general practice (direct admission or after 
consulting the duty hospital doctor), outpatient clinics, or by urgent transfer from 
another hospital. 
We calculated presentation rate, which was the unit of analysis, by dividing the 
number of visits by observation time. Changes in the pattern of hospital presentations 
were estimated using a cohort of patients with linked HES records, and changes in 
the pattern of primary care presentations were estimated from a separate cohort of 
patients with linked CPRD records. The observation time for each patient in HES 
began on the later of the date of birth or the start date of the HES data and ended 
with the earlier of the date of death or the end date of HES data. The observation 
time in CPRD began on the date of registration with the general practice (most took 
place within a few weeks after birth) and ended with the earliest of the date of death, 
transferring out (if a patient had moved to a practice not contributing data to CPRD) 
or last collection date (when a practice last submitted data to CPRD). Presentation 
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rates may thus be interpreted as the number of visits per month in a cohort of 100 
patients. We described temporal changes in the presentation rates from the date of 
diagnosis in the National Cancer Registry for 0–1, 1–3, 3–6, 6–12 and over 12 
months in the main text.26, 27 But since time from diagnosis when patients presented 
is continuous in nature, we have also illustrated changes in presentation rate 
graphically (in supplemental materials) to overcome the arbitrariness of dividing time 
into intervals, especially for presentations that took place exactly at the boundary of 
those intervals. Although we are primarily interested in presentations before the 
diagnosis of an intracranial tumour, presentations after diagnosis have been included 
for two reasons: (a) to demonstrate, rather than to assume, that the intensity of 
healthcare use falls after a diagnosis and thus emphasise the importance of reaching 
a correct diagnosis; and (b) to reduce statistical uncertainty in estimating rates 
around the time of diagnosis by placing the important observations at the centre of 
the dataset. Estimation of rate ratios and their 95% confidence intervals was carried 
out in generalised linear models, with smoothing in the time domain using 
generalised additive models with locally weighted regression (LOESS) to highlight 
the underlying trend.28-31 
We analysed our data in the statistical language R, with functions from the ‘gam’ 
package.32, 33 Computationally intensive calculations were carried out on the High 
Performance Computing cluster at the London School of Hygiene and Tropical 
Medicine. 
3. Results 
Among 9,799 brain tumour patients diagnosed aged 0–24 years between 1989 and 
2006 and registered in the National Cancer Registry, we linked 181 individuals to 
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3,787 primary care records from CPRD. Of the 5,061 patients diagnosed in the 
period 1997–2006, we linked 3,959 patients to 60,351 in-patient admission records 
from HES. The characteristics of patients with linked records have been discussed 
elsewhere.13 Briefly, the distributions in age and sex were similar between patients 
with and without linked records when compared with the National Cancer Registry, in 
which the data came from the general population. Tumours in the supratentorial 
compartment or the midline were more likely to be linked to CPRD and peri-
ventricular tumours less so. For HES linkage, cerebellar and brainstem tumours were 
more likely to have linked records whereas midline tumours were less likely. 
3.1. Primary care consultations 
Consultation rates varied between tumour locations, after accounting for the effects 
of age and year of diagnosis (likelihood ratio test statistic = 122.8, P < 0.001). 
Patients with a peri-ventricular tumour had the highest pre-diagnosis presentation 
frequency (mean = 11.5 consultations per 100 persons each month, Table 1), and 
was 1.12 times (95% CI = 0.62–1.85) higher than in patients with a supratentorial 
tumour. Patients with a tumour in the midline (rate ratio = 0.52; 95% CI = 0.42–0.64), 
brainstem (0.48; 0.35–0.64), cerebellum (0.47; 0.37–0.59), the meninges (0.24; 
0.14–0.38) or the cranial nerves (0.87; 0.58–1.27) presented less often than 
supratentorial tumours, that is, between 2.4 and 6.5 consultations per 100 persons 
each month in those patients. 
Consultation rates peaked in the final month before diagnosis at rates over 100 
consultations per 100 persons (Supplemental Table S.1). Patients with a tumour in 
the supratentorial compartment, the midline or cranial nerves were seen with steadily 
increasing frequency before diagnosis (Figures 1 and 2). Patients with a tumour in 
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the cerebellum, brainstem, ventricular system or the meninges seldom presented 
until about six months before diagnosis (Supplemental Figure S.3–S.6, left). The 
frequency of consultations remained raised 12 months after a brain tumour diagnosis 
(Supplemental Table S.1). 
Convulsion was the commonest feature of tumours in the supratentorial compartment 
(8.7% of consultations), ventricular system (28.0%) and meninges (27.3%). Disorders 
of growth or endocrine functions were common in midline tumours (15.5%). 
Headaches were the dominant feature of tumours in the brainstem (7.9%), 
cerebellum (6.2%), midline (11.5%) and ventricles (10.0%). Dysfunction of cranial 
nerves II, III, IV or VI was also commonly seen in tumours in the supratentorial 
compartment (6.9%), midline (9.5%), ventricular system (10.0%) and cranial nerves 
(13.4%). Non-specific symptoms were common in brainstem (6.8%) or meninges 
(7.8%) tumours. Focal neurological deficits were rarely seen. 
3.2. Hospital presentations 
Similar to the pattern in primary care, the presentation rates varied between tumour 
sites after accounting for age and year of diagnosis (likelihood ratio test statistic = 
106.5, P < 0.001; and for emergency presentations only: 87.2; P < 0.001). Patients 
with a peri-ventricular tumour were most frequently admitted to hospitals (rate = 5.4 
admissions per 100 persons each month, which was 1.29 times (95% CI = 1.12–
1.48) that of supratentorial tumours, Table 1), and often as an emergency (2.5 
admissions per 100 persons each month, which was 1.24 times (95% CI = 1.01–
1.51) that of supratentorial tumours). Tumours outside the ventricular system 
presented less frequently than supratentorial tumours, with the exception of 
cerebellar tumours which presented as emergency with a rate 10% higher than 
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supratentorial tumours (rate ratio = 1.10, 95% CI = 0.99–1.22). 
Admissions were the most frequent within one month around the diagnosis of an 
intracranial tumour, with rates over 100 admissions per 100 persons each month 
(Supplemental Table S.2). Patients were seldom admitted urgently with any relevant 
symptoms until the final 3–6 months before diagnosis (Supplemental Table S.3). A 
sudden rise in urgent admissions was seen in patients with tumours in the 
cerebellum (Figure 3), brainstem (Figure 4) or supratentorial compartment than in 
peri-ventricular, midline, meninges or cranial nerve tumours (Supplemental Figure 
S.5-S.7, right). 
The commonest reason for admission was convulsion in patients with a tumour in the 
supratentorial compartment (11.3% of admissions) or meninges (21.6%). Raised 
intracranial pressure was the commonest reason in cerebellar (16.1%), brainstem 
(16.5%) or peri-ventricular tumours (18.0%), and the second commonest reason for 
tumours in the supratentorial compartment (10.0%), midline (12.8%), meninges 
(14.0%) or cranial nerves (11.6%). Growth or endocrine disorders were the 
commonest in midline tumours (24.5%). Focal neurological deficits were uncommon 
(fewer than in 5% of admissions). 
4. Discussion 
Children and young adults with an intracranial tumour begin presenting six months 
before diagnosis in primary care and three months before diagnosis in hospital. 
These contacts with healthcare professionals in primary care and in hospitals 
represent opportunities for an earlier diagnosis. 
Patients may visit Accident and Emergency with very few primary care consultations 
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(as in cerebellum or brainstem tumours, Figures S.3 and S.4), or may have a greater 
number of such consultations before referral to a specialist (supratentorial or midline 
tumours, Figures S.1 and S.2). A consultation rate of over 100 per 100 person-
months in the final month implies each patient may, on average, be seen at least 
once in primary care before the diagnosis of an intracranial tumour. Hospital 
admissions, especially for emergency presentations, also occur most frequently in 
the final month. These patterns imply a definitive diagnosis may be brought forward 
by at least one month for many intracranial tumours, or even earlier for tumours 
arising in the supratentorial compartment, in the midline or in cranial nerves. Many 
midline and cranial nerve tumours are craniopharygiomas (ICD-Oncology 
morphology code: 9350), germ cell tumours (9064), pineal tumours (9362) or 
Schwannomas (9560), which are slow-growing and likely to cause multiple 
presentations of less acute symptoms, offering opportunities for earlier detection in 
their natural history to reduce morbidity associated with their symptoms.34 Consistent 
with earlier studies, we found convulsion to be the commonest symptom of 
supratentorial tumours in primary care and in hospitals, followed by ophthalmic signs 
in primary care and features of raised intracranial pressure in secondary care.6, 35 
Midline tumours are likely to present with loss of visual field and acuity, 
endocrinopathy or growth and developmental disorders,6, 36-38 features that are more 
likely to trigger a visit to the general practitioner early in the course of their natural 
history. Since focal neurological deficits are uncommon, particularly early in the 
natural history of intracranial tumours,13 examining for their presence plays very little 
role in bringing forward the diagnosis of a brain tumour. Early clinical features to 
watch out for, in both primary care and hospital settings, include convulsions, growth 
or endocrine disorders and recurrent headaches. First presentation of a seizure, 
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especially a non-febrile seizure, should be evaluated by a paediatrician or a 
physician with training and expertise in epilepsy, and referred to tertiary service for 
any doubtful diagnosis or treatment failure.39 
Cerebellar or brainstem tumours are expected to present commonly with loss of 
balance and coordination, cranial nerve dysfunction, focal neurological deficits and 
long-tract signs.36-38 We found tumours in the cerebellum or the brainstem, parts of 
the brain close to vital structures, rarely present in primary care much earlier than 
when the tumours are currently diagnosed when raised intracranial pressure 
develops to the extent that an urgent hospital visit becomes necessary. This means 
the diagnosis time for posterior fossa tumours has already reached an optimal level 
under current technology, and the scope for further reduction is limited. 
4.1. Strengths and limitations 
Many studies about symptoms and signs were limited to examining a snapshot close 
to a diagnosis date from interviews or review of medical notes after the researchers 
and the patients (or their parents) were fully aware of the true diagnosis.2-5, 40, 41 We 
were able to use the official diagnosis date in the National Cancer Registry, which is 
derived under international standards, as our end-point for the pre-diagnosis period 
to ensure consistency across individuals in the measurement of timing of primary 
care consultations and hospital visits.26, 27 We also developed a pre-defined list of 
symptoms and signs to search for relevant presentations in primary care (CPRD) and 
hospital (HES) records to ensure comparability between different cohorts and 
reproducibility of our findings in future studies, especially for investigating trends in 
clinical care. 
We were unable to examine more closely the temporal pattern of symptoms and 
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signs specific to each tumour location because of the small number of patients with 
linked primary care records: the population coverage of CPRD was 5–10% when our 
study was carried out. These have limited the certainty of our findings, but we have 
analysed primary care and hospital use in the largest population-based cohort of 
children with a histologically verified brain tumour available in England. This cohort of 
patients would otherwise be logistically difficult to create and follow up prospectively 
due to low incidence of childhood brain tumours. 
Variations in the proportion of patients with linked records are due to differences in 
the probability of healthcare use. Tumours with a greater chance of requiring urgent 
interventions in hospitals (e.g. cerebellar, brainstem or peri-ventricular tumours) are 
found to be less likely to have presented in primary care, and therefore a linked 
record. The behaviour of those tumours are more fast-growing and they also 
originate in locations close to vital areas in the brain (brainstem) or in strategic sites 
that may cause life-threatening complications such as raised intracranial pressure 
(peri-ventricular). These two factors, in combination, reduced the chances for those 
tumours to be detected in primary care and contributed to the development of 
complications requiring urgent intervention. 
The presence of a CPRD or HES record implies one or more clinical features have 
caused sufficient concern to the patient (or parents) to seek medical advice, and the 
symptoms and signs on record are those that were interpreted as important by the 
clinician who saw the patient. Although they may not represent the complete picture 
of presenting features, decisions on investigations and treatment were often made on 
the basis of medical records.42, 43 Thus, CPRD and HES data are reasonably 
representative of the information that were used in deciding diagnosis and treatment 
strategy in cancer patients. 
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4.2. Conclusion and implications 
Many patients present to primary care and hospitals with increasing frequency until 
the eventual diagnosis of their brain tumours. The gradual increase in the frequency 
of primary care visits by patients with supratentorial, midline or cranial nerve tumours 
in the six-month period before diagnosis provides opportunities for an earlier 
diagnosis. The scope for earlier detection of cerebellar, brainstem or peri-ventricular 
tumours is more limited since the frequency of their presentation in primary care or in 
hospitals was very low before their diagnosis. 
Common features of intracranial tumours in primary care are headaches, 
convulsions, growth and endocrine disorders, and cranial nerve II, III, IV or VI 
dysfunction.5, 13, 28, 35, 44 Presentations of these clinical features, especially when 
occurring repeatedly, should trigger further investigations into the possibility of an 
intracranial tumour. Features of raised intracranial pressure or focal neurological 
deficits are late signs more likely seen in emergency hospital admissions.  
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Figure 1. Pattern of primary care presentations in children and young adults with a 
supratentorial tumour before and after diagnosis (time = 0): England, 1989–2006. 
Change in monthly presentation rates (grey dots) after LOESS smoothing (solid line).  
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Figure 2. Pattern of primary care presentations in children and young adults with a 
midline tumour before and after diagnosis (time = 0): England, 1989–2006. 
Change in monthly presentation rates (grey dots) after LOESS smoothing (solid line).  
050
100
150
200
250
Midline
Time from diagnosis (months)
C
on
su
lta
tio
n 
ra
te
 (p
er
 1
00
 p
er
so
n−
m
on
th
s)
36 24 12 0 12 24 36
Before diagnosis After diagnosis
22 
Figure 3. Pattern of hospital presentations in children and young adults with a 
cerebellar tumour before and after diagnosis (time = 0): England, 1997–2006. 
Change in monthly rates of all presentations (black dots) after LOESS smoothing 
(black line), and of emergency presentations (red dots) after LOESS smoothing (red 
line).  
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Figure 4. Pattern of hospital presentations in children and young adults with a 
brainstem tumour before and after diagnosis (time = 0): England, 1997–2006. 
Change in monthly rates of all presentations (black dots) after LOESS smoothing 
(black line), and of emergency presentations (red dots) after LOESS smoothing (red 
line). 
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Table 1: Presentation rate (per 100 person-months) before an intracranial tumour diagnosis from CPRD (1989–2006) and HES-linked registrations (1997–2006) in 
patients aged 0 to 24 years in England.
Primary care presentations Hospital presentations
All admissions Emergency only
Count Rate
Rate 
ratio* 95% CI Count Rate
Rate 
ratio* 95% CI Count Rate
Rate 
ratio* 95% CI
Supratentorial 382 9.8 1.00 reference 1,981 3.7 1.00 reference 951 1.8 1.00 reference
Midline 144 5.2 0.52 0.42 – 0.64 668 2.7 0.81 0.74 – 0.88 304 1.2 0.79 0.69 – 0.90
Cerebellum 85 4.4 0.47 0.37 – 0.59 967 3.5 0.84 0.77 – 0.91 623 2.3 1.10 0.99 – 1.22
Brainstem 47 4.8 0.48 0.35 – 0.64 585 3.2 0.80 0.73 – 0.88 352 1.9 0.98 0.87 – 1.11
Ventricles 14 11.5 1.12 0.62 – 1.85 227 5.4 1.29 1.12 – 1.48 105 2.5 1.24 1.01 – 1.51
Meninges 17 2.4 0.24 0.14 – 0.38 168 2.4 0.78 0.66 – 0.91 74 1.1 0.73 0.57 – 0.92
Cranial nerves 32 6.5 0.87 0.58 – 1.27 147 1.9 0.58 0.48 – 0.68 44 0.6 0.37 0.27 – 0.50
Other 234 5.0 0.49 0.42 – 0.58 2,230 3.5 0.91 0.85 – 0.96 1,187 1.8 1.00 0.92 – 1.09
* Estimated rate ratios were adjusted for age and year of diagnosis.
CPRD = Clinical Practice Research Datalink, HES = Hospital Episode Statistics.
Table S.1: Primary care presentation rate (per 100 person-months) from CPRD-linked registrations in intracranial tumour patients 
aged 0 to 24 years, England, 1989–2006: by tumour location and time from diagnosis.
Supratentorial Midline Cerebellum Brainstem
Time from diagnosis
(months) Rate 95% CI Rate 95% CI Rate 95% CI Rate 95% CI
Before diagnosis
12+ months 6.7 5.9 – 7.6 1.6 1.1 – 2.2 1.9 1.3 – 2.7 1.0 0.5 – 1.9
6–12 12.3 8.7 – 17.5 10.5 6.5 – 16.9 4.2 1.9 – 9.3 4.2 1.3 – 12.9
3–6 29.9 21.8 – 40.9 18.5 11.2 – 30.7 0.0 not estimated 5.2 1.3 – 20.9
1–3 28.9 19.7 – 42.4 43.6 29.2 – 65.1 14.0 6.7 – 29.4 18.8 7.8 – 45.1
0–1 month 109.4 83.2 – 144.0 167.1 125.5 – 222.4 156.0 114.0 – 213.5 193.6 133.7 – 280.4
After diagnosis
0–1 month 125.0 97.1 – 161.0 125.0 89.7 – 174.1 112.0 77.3 – 162.2 100.0 61.3 – 163.2
1–3 50.9 38.3 – 67.5 57.1 40.4 – 80.8 46.9 30.9 – 71.3 64.2 40.4 – 101.9
3–6 39.1 29.8 – 51.1 41.8 30.0 – 58.3 55.1 40.1 – 75.7 50.0 31.5 – 79.4
6–12 26.9 21.3 – 34.0 18.5 12.8 – 26.8 38.3 29.1 – 50.4 41.9 28.8 – 61.1
12+ months 22.3 20.5 – 24.3 16.2 14.7 – 17.9 15.6 13.7 – 17.6 14.7 11.5 – 18.9
Ventricles Meninges Cranial nerves Other
Time from diagnosis
(months) Rate 95% CI Rate 95% CI Rate 95% CI Rate 95% CI
Before diagnosis
12+ months 4.1 1.5 – 10.9 1.2 0.6 – 2.4 2.7 1.5 – 4.8 2.2 1.8 – 2.7
6–12 8.3 1.2 – 59.2 0.0 not estimated 25.0 13.0 – 48.0 5.6 3.4 – 9.3
3–6 0.0 not estimated 0.0 not estimated 16.7 5.4 – 51.7 11.9 7.3 – 19.3
1–3 50.0 12.5 – 199.9 30.0 9.7 – 93.0 7.5 1.1 – 53.1 25.1 16.7 – 37.7
0–1 month 150.0 48.4 – 465.1 100.0 41.6 – 240.3 71.4 29.7 – 171.6 176.3 142.2 – 218.7
After diagnosis
0–1 month 100.0 25.0 – 399.8 60.0 19.4 – 186.0 28.6 7.1 – 114.2 122.7 94.0 – 160.2
1–3 25.0 3.5 – 177.5 10.0 1.4 – 71.0 35.7 14.9 – 85.8 39.5 27.9 – 55.8
3–6 0.0 not estimated 13.3 3.3 – 53.3 4.8 0.7 – 33.8 42.3 31.9 – 55.9
6–12 0.0 not estimated 20.0 9.0 – 44.5 2.4 0.3 – 16.9 28.5 22.2 – 36.5
12+ months 13.9 9.9 – 19.6 10.0 7.5 – 13.2 20.1 17.1 – 23.5 17.7 16.4 – 19.2
CPRD = Clinical Practice Research Datalink.
Table S.2: Hospital presentation rate (per 100 person-months) from HES-linked registrations in intracranial tumour patients aged 
0 to 24 years, England, 1997–2006: by tumour location and time from diagnosis.
Supratentorial Midline Cerebellum Brainstem
Time from diagnosis
(months) Rate 95% CI Rate 95% CI Rate 95% CI Rate 95% CI
Before diagnosis
12+ months 0.6 0.5 – 0.7 0.3 0.2 – 0.3 0.1 0.1 – 0.2 0.2 0.1 – 0.3
6–12 2.4 2.0 – 2.8 1.4 1.0 – 2.0 0.5 0.3 – 0.9 0.2 0.1 – 0.5
3–6 3.8 3.2 – 4.6 2.8 2.0 – 4.0 1.0 0.6 – 1.6 1.0 0.6 – 1.9
1–3 7.4 6.3 – 8.7 10.3 8.3 – 12.8 2.1 1.4 – 3.1 6.4 4.8 – 8.6
0–1 month 132.1 125.2 – 139.4 114.1 104.2 – 125.0 151.8 142.1 – 162.1 137.6 126.0 – 150.3
After diagnosis
0–1 month 102.4 96.3 – 108.9 84.6 76.1 – 94.1 118.4 109.9 – 127.6 159.1 146.4 – 173.0
1–3 92.7 88.6 – 97.1 81.2 75.2 – 87.6 183.8 176.1 – 191.9 129.2 120.7 – 138.2
3–6 62.3 59.4 – 65.2 53.7 49.7 – 58.0 125.4 120.1 – 130.9 66.5 61.4 – 72.1
6–12 46.3 44.5 – 48.1 28.5 26.4 – 30.7 91.3 88.1 – 94.7 59.4 55.5 – 63.5
12+ months 16.1 15.7 – 16.5 5.9 5.5 – 6.2 14.2 13.8 – 14.7 17.0 16.1 – 18.0
Ventricles Meninges Cranial nerves Other
Time from diagnosis
(months) Rate 95% CI Rate 95% CI Rate 95% CI Rate 95% CI
Before diagnosis
12+ months 1.5 1.1 – 2.0 0.3 0.2 – 0.5 0.2 0.1 – 0.3 0.4 0.3 – 0.4
6–12 1.0 0.4 – 2.5 1.3 0.7 – 2.7 0.8 0.4 – 1.8 1.0 0.8 – 1.3
3–6 2.6 1.3 – 5.6 2.3 1.1 – 4.8 1.8 0.9 – 3.8 2.4 1.9 – 2.9
1–3 10.4 6.7 – 16.4 4.4 2.3 – 8.4 4.9 2.9 – 8.5 6.2 5.3 – 7.3
0–1 month 160.6 136.8 – 188.5 123.3 103.6 – 146.7 82.1 68.1 – 99.0 137.0 130.7 – 143.7
After diagnosis
0–1 month 90.6 73.0 – 112.5 31.2 22.0 – 44.1 23.3 16.4 – 33.2 95.1 89.8 – 100.8
1–3 135.0 119.0 – 153.1 16.2 11.5 – 22.8 15.2 11.1 – 20.7 105.3 101.2 – 109.5
3–6 90.0 79.2 – 102.3 16.0 12.1 – 21.2 9.1 6.6 – 12.6 73.8 71.0 – 76.7
6–12 68.6 61.6 – 76.3 12.2 9.7 – 15.3 7.5 5.8 – 9.6 60.7 58.8 – 62.6
12+ months 18.8 17.6 – 20.1 4.2 3.6 – 4.8 3.0 2.7 – 3.5 15.6 15.2 – 15.9
HES = Hospital Episode Statistics.
Table S.3: Emergency presentation rate (per 100 person-months) from HES-linked registrations in intracranial tumour patients 
aged 0 to 24 years, England, 1997–2006: by tumour location and time from diagnosis.
Supratentorial Midline Cerebellum Brainstem
Time from diagnosis
(months) Rate 95% CI Rate 95% CI Rate 95% CI Rate 95% CI
Before diagnosis
12+ months 0.2 0.2 – 0.2 0.1 0.1 – 0.2 0.1 0.1 – 0.1 0.1 0.0 – 0.1
6–12 1.0 0.7 – 1.3 0.6 0.4 – 1.1 0.4 0.3 – 0.7 0.1 0.0 – 0.4
3–6 1.9 1.5 – 2.5 0.9 0.5 – 1.7 0.9 0.5 – 1.5 0.9 0.4 – 1.6
1–3 4.3 3.4 – 5.3 4.2 3.0 – 5.8 1.2 0.7 – 2.0 2.9 1.9 – 4.5
0–1 month 66.8 62.0 – 72.1 54.8 48.0 – 62.4 96.3 88.7 – 104.6 86.2 77.1 – 96.3
After diagnosis
0–1 month 21.9 19.1 – 25.0 22.4 18.2 – 27.5 38.5 33.7 – 43.9 41.1 34.9 – 48.4
1–3 15.2 13.5 – 17.0 14.2 11.8 – 17.0 26.8 24.0 – 30.0 19.7 16.6 – 23.4
3–6 10.5 9.4 – 11.8 11.1 9.4 – 13.2 16.5 14.6 – 18.5 13.8 11.6 – 16.5
6–12 8.2 7.4 – 9.0 4.8 4.0 – 5.8 11.8 10.7 – 13.1 11.2 9.6 – 13.1
12+ months 3.0 2.8 – 3.2 1.3 1.2 – 1.5 2.0 1.9 – 2.2 2.9 2.6 – 3.3
Ventricles Meninges Cranial nerves Other
Time from diagnosis
(months) Rate 95% CI Rate 95% CI Rate 95% CI Rate 95% CI
Before diagnosis
12+ months 0.5 0.3 – 0.8 0.2 0.1 – 0.3 0.1 0.0 – 0.2 0.1 0.1 – 0.2
6–12 0.2 0.0 – 1.5 0.8 0.4 – 2.0 0.3 0.1 – 1.1 0.5 0.3 – 0.7
3–6 1.1 0.4 – 3.5 1.6 0.7 – 3.9 1.0 0.4 – 2.7 1.3 1.0 – 1.8
1–3 2.2 0.8 – 5.9 1.9 0.7 – 5.2 2.7 1.3 – 5.6 3.7 3.0 – 4.5
0–1 month 88.4 71.2 – 109.7 49.5 37.6 – 65.2 19.4 13.2 – 28.5 75.9 71.2 – 80.9
After diagnosis
0–1 month 24.3 16.0 – 36.9 11.7 6.6 – 20.6 9.8 5.7 – 16.9 28.6 25.7 – 31.8
1–3 21.1 15.4 – 29.0 5.9 3.3 – 10.4 3.0 1.5 – 6.1 18.7 17.0 – 20.5
3–6 16.9 12.6 – 22.7 4.3 2.5 – 7.3 1.5 0.7 – 3.4 13.3 12.2 – 14.6
6–12 10.7 8.2 – 14.1 3.3 2.1 – 5.1 1.3 0.7 – 2.3 10.4 9.6 – 11.2
12+ months 3.6 3.1 – 4.2 2.0 1.6 – 2.4 0.5 0.3 – 0.7 2.9 2.7 – 3.0
HES = Hospital Episode Statistics.
Supplementary materials 
Figures 
● Figures represent temporal change in presentation rate in children and young adults 
with intracranial tumour, by anatomical location, before and after diagnosis (time = 0 
at brain tumour diagnosis) in England. 
● Left column: primary care presentations (1989–2006) 
○ grey dots: observed rates 
○ black line: predicted rates after locally weighted regression (LOESS) 
smoothing 
● Right column: hospital presentations (1997–2006) 
○ black dots: observed rates of all admissions 
○ red dots: observed rates of emergency admissions only 
○ black line: predicted rates of all admissions after LOESS smoothing 
○ red line: predicted rates of emergency admissions after LOESS smoothing 
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